Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

NCT03144856 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: Apatinib

Sponsor

Sun Yat-sen University

Collaborators

[object Object]